Setterwalls has advised LIDDS AB (publ) in connection with rights issue of approximately SEK 48.6 million

Setterwalls has advised LIDDS AB (publ) in connection with rights issue of approximately SEK 48.6 million.

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. The company is listed on Nasdaq First North Growth Market.